Tuesday, December 6 — 12:45-14:15
WHAT’S NEW IN PNEUMOCOCCAL DISEASE? WHERE HAVE WE BEEN AND WHERE ARE WE GOING?
Pneumococcal disease causes severe infections such as meningitis, bacteraemia and pneumonia, with children and the elderly being at greatest risk for infection. The success of pneumococcal vaccination programs across Canada can be seen with PCV13 serotypes having declined in all ages, with an overall decline from 45.6% in 2010 to 26.0% in 2014. PCV13 has a significant added benefit over PCV7 in reducing carriage of antibiotic-nonsusceptible Streptococcus pneumonia (ANSP). Because carriage determines transmission, these results suggest that PCV13 will provide protection ANSP disease that exceeds protection provided by PCV7.
Unfortunately, adults are still not effectively protected. The rate of pneumococcal pneumonia in adults 50 to 64 years and ≥65 years is higher among persons with comorbidities vs. healthy counterparts; and a patient’s comorbidities increase their risk of mortality associated with pneumococcal disease. NACI recently published recommendations for pneumococcal vaccinations that will hopefully contribute to the prevention of vaccine-type community-acquired pneumonia and IPD in the adult population.
After attending this symposium, participants will be able to:
- Review the burden of pneumococcal disease and the introduction and impact of pneumococcal vaccinations in Canada.
- Describe the importance of reducing nasopharyngeal carriage of S. pneumonaie.
- Examine the unmet need of pneumococcal disease protection in the adult population.
- Discuss the importance of adult pneumococcal vaccination and review the implementation of NACI recommendations.
- James Kellner, MD, Professor and Head, Department of Pediatrics, University of Calgary
- Ron Grossman, MD, Professor of Medicine, University of Toronto, Chief of Medicine, Credit Valley Hospital
The program was co-developed with CPS and Pfizer Canada Inc and was planned to achieve scientific integrity, objectivity and balance.